Evette Hillman

Ms. Evette Hillman


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2021 in Microbiology Research
Verified
Journal Article
Open access
PDF file
EHEvette Hillman
Evette Hillman
SRSjoerd Rijpkema
Sjoerd Rijpkema
DCDanielle Carson
Danielle Carson
RARamesh Arasaradnam
Ramesh Arasaradnam
EWElizabeth M. H. Wellington
Elizabeth M. H. Wellington
GAGregory C.A. Amos
Gregory C.A. Amos
Bile acid diarrhoea (BAD) is a widespread gastrointestinal disease that is often misdiagnosed as irritable bowel syndrome and is estimated to affect 1% of the United Kingdom (UK) population alone. BAD is associated with excessive bile acid synthesis secondary to a gastrointestinal or idiopathic disorder (also known as primary BAD). Current licensed treatment in the UK has undesirable effects and has been the same since BAD was first discovered in the 1960s. Bacteria are essential in transforming primary bile acids into secondary bile acids. The profile of an individual’s bile acid pool is central in bile acid homeostasis as bile acids regulate their own synthesis. Therefore, microbiome dysbiosis incurred through changes in diet, stress levels and the introduction of antibiotics may contribute to or be the cause of primary BAD. This literature review focuses on primary BAD, providing an overview of bile acid metabolism, the role of the human gut microbiome in BAD and the potential options for therapeutic intervention in primary BAD through manipulation of the microbiome.

27 May 2025 in Gastro Hep Advances
Verified
Journal Article
Open access
EHEvette Hillman
Evette Hillman
DCDanielle Carson
Danielle Carson
JWJulian Walters
Julian Walters
MFMartin Fritzsche
Martin Fritzsche
RMRyan Mate
Ryan Mate
GAGregory C.A. Amos
Gregory C.A. Amos
Bile acid diarrhea (BAD) is a common cause of frequent loose stools, urgency, and incontinence, which is under-recognized due to limited diagnostic test availability and unclear pathogenesis. This study aimed to investigate fecal changes in well-defined subjects. Fecal samples were compared in BAD patients (n = 26), diagnosed by SeHCAT testing, and healthy controls (n = 21). Shotgun metagenomic sequencing was used to identify microbiome species and functional genes. An extended set of 38 bile acids was quantified by liquid chromatography mass spectrometry, including various epimers and intermediates, such as iso- (3-beta-OH), oxo (keto), allo (5-alpha), and 3-sulfated forms. Alpha diversity, reflecting microbial richness, was reduced in BAD patients with severe forms of the disease, while beta diversity demonstrated distinct microbial profiles between groups. Ruminococcus gnavus (R. gnavus) was prevalent in BAD patients but rare in controls (odds ratio = 73), while Firmicutes bacterium CAG110, Eubacterium siraeum and 2 Oscillibacter species were less common in BAD (odds ratios = 25–30). Overall, 99 taxa differed significantly between groups. Bile acidtransforming genes (baiA, baiB, hdhA) were more abundant in BAD samples (P ≤ .0012). Most fecal bile acids, including iso-bile acids and intermediates, were higher in BAD. Elevated ursodeoxycholic acid-3-sulfate and relatively lower lithocholic acid and allo-bile acids, including isoallolithocholic acid, reflect changes in bacterial metabolism. Biofilm-associated genes (bssS, pgaA, pgaB) were markedly elevated in BAD patients (P ≤ .00008). SeHCAT values negatively correlated with R. gnavus (rho −0.53, P = .008) and positively with E ubacterium siraeum (rho 0.41, P = .041). BAD may result from an overgrowth of R. gnavus, associated with intestinal biofilms and an altered bile acid metabolism.

20 May 2025 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
EHEvette Hillman
Evette Hillman
MBMaximilian Baumgartner
Maximilian Baumgartner
DCDanielle Carson
Danielle Carson
GAGregory C. A. Amos
Gregory C. A. Amos
IWImad Wazir
Imad Wazir
SLStephen J. Lewis
Stephen J. Lewis
Background: The specific influence of whole gut transit time (WGTT) on microbiome dynamics and bile acid metabolism remains unclear, despite links between changes in WGTT and certain gastrointestinal disorders. Our investigation aimed to determine the impact of WGTT changes on the composition of the fecal microbiome and bile acid profile.Methods: Healthy volunteers (n = 18) received loperamide, to decrease bowel movement frequency, and senna, a laxative, each over a 6‐day period, in a randomized sequence, with a minimum 16‐day interval between each treatment. Stool samples were analyzed for microbiome by shotgun sequencing and bile acid composition determined with high‐performance liquid chromatography coupled to tandem mass spectrometry. Sera were examined for markers of bile acid synthesis.Key Results: Senna or loperamide decreased or increased WGTT, respectively. Treatment altered stool characteristics, bowel movement frequency, and stool weight. The senna‐treated group had increased primary and secondary fecal bile acids; serum levels of fibroblast growth factor 19 were significantly reduced. Increasing WGTT with loperamide led to an increase in bile salt hydrolase genes, along with elevated bacterial species richness (p = 0.04). Thirty‐six species exhibiting significant differences were identified, several of which have notable implications for gut health. WGTT displayed negative correlations with total primary (particularly chenodeoxycholic acid) and secondary bile acids (ursodeoxycholic acid and glycochenodeoxycholic acid). Treatment‐induced changes in microbiome composition and bile acid metabolism reverted back to baseline within 16 days.Conclusion: Whole gut transit time changes significantly affect fecal microbiome composition and function, as well as bile acid composition and synthesis in healthy subjects. This consideration is likely to have long‐term implications.